EAM
CNTA

Exome Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Exome Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
+34,700
New +$888K 0.71% 45
2025
Q4 		– Sell
-25,000
Closed -$606K – 67
2025
Q3 		$606K Buy
+25,000
New +$444K 0.37% 57

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Exome Asset Management's CNTA Position: Q4 2025 in Review

Exome Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 88,024 shares — an estimated $2.13M sold.

Exome Asset Management first reported a position in CNTA in Q1 2024 and held it in 7 quarters. The position peaked at $3.11M in Q1 2024. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Exome Asset Management reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Exome Asset Management sold 88,024 Centessa Pharmaceuticals shares in Q4 2025, an estimated $2.13M.
  • Exome Asset Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Exome Asset Management's Centessa Pharmaceuticals position peaked at $3.11M in Q1 2024.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.